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A b s t r a c t
Meningiomas are one of the most frequent intracranial tumours, with 13 histological types and three grades accord-
ing to the 2007 WHO Classiﬁcation of Tumours of the Central Nervous System. p53, as one of the most potent 
tumour suppressor proteins, plays a role in nearly 50% of human tumours. Poly(ADP-ribose) polymerase (PARP) is 
a DNA repair enzyme with high ATP demand. It plays a role in apoptosis by activating an apoptosis inducing factor, 
and in necrosis by consuming NAD+ and ATP. Only PARP1 has been investigated in detail in tumours out of the 
17 members of the PARP superfamily; however, its role has not been studied in meningiomas yet. The aim of this 
study was to determine the role of p53 and PARP1 in meningiomas of different grade and to establish whether there 
is any correlation between the p53 and PARP1 expression. Both PARP1 and p53 have been expressed in all examined 
meningiomas. PARP1 labelled grade II tumours with a higher intensity as compared to grade I and III neoplasms, 
respectively. An increased p53 expression was noted in grade III meningiomas. There was no statistical correlation 
between p53 and PARP1 expression. Our data indicate that both PARP1 and p53 activation is a feature in menin-
giomas of higher grade, PARP1 overexpression being an early, whereas p53 overexpression, a late event in tumour 
progression.
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Meningiomas are frequent primary brain tu mours 
representing approximately 30% of all primary intra-
cranial tumours. The incidence is increasing with 
age and has a  slight female predominance [32,59]. 
The aetiology is not entirely understood, but the 
increased risk after whole brain radiation therapy 
is well known [38]. There are several subtypes, like 
meningothelial, fibrous, transitional, psammoma-
tous, angiomatous, microcystic, secretory, lympho-
plasmacyte-rich, sometimes with crystalline inclu-
sions [5], metaplastic, choroid, clear cell, rhabdoid, 
papillary and other rare or miscellaneous types [34]. 
According to the ultrastructural findings, some of 
the intranuclear vacuoles are produced during auto-
phagy [18]. The heterogeneous glycosylation pattern 
has also been demonstrated in different subtypes of 
meningiomas, and it indicates the usefulness of lec-
tins in the evaluation of pluripotential differentiation 
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of meningioma cells [56]. The current prediction of 
clinical behaviour is based on the morphological find-
ings, brain invasion, mitosis index and Mib1 immu-
nostaining [1,47,48]. Meningiomas show positive 
immunoreactivity for epithelial membrane antigen, 
oestrogen and progesterone receptors [45]; howev-
er these immunohistochemical markers do not help 
with the determination of the grade. CD31 immuno-
staining is good for revealing the blood vessel num-
ber that is higher in atypical meningiomas than WHO 
grade I tumours [31], but this marker is not used in 
routine diagnostic work-up. Despite these findings, 
there is a  need for more “malignant” markers for 
meningiomas that can be used in routine diagnostic 
work and a group of them could be the DNA repair 
genes like p53 or poly(ADP-ribose) polymerase (PARP) 
in the future.
PARP protein superfamily has 17 members. All 
of them have four domains: catalytic, auto-modifi-
cation, caspase-cleaved and DNA-binding domain. 
Some of them have PARP activity, as PARP1 or PARP2 
and some of them do not, as PARP3 or PARP6.
PARP1 is a 113 kDa protein, located in the nucle-
us. The gene of PARP1 is located on the long arm 
of chromosome 1 (1q42.12). The cDNA was isolated 
and sequenced first by Kurosaki et al. [26]. One of 
the main functions of PARP1 is its role in the repair 
of single-stranded DNA breaks (SSB). After detecting 
the SSB damage by chemical, radiation or metabolic 
induction, the enzyme is activated and binds to the 
DNA, undergoes a structural transformation before 
it produces poly(ADP-ribose) (PAR) chain by a nico-
tinamide adenine dinucleotide (NAD+), consuming 
the process. PAR is a  signal for other repair genes 
during base excision repair (BER) [9,29,35]. Activat-
ed PARP1 can poly(ADP-ribosyl)ate (PARylate) nucle-
ar enzymes thereby increasing the negative charge 
and preventing the interaction with other anionic 
molecules including the DNA. Among the DNA repair 
functions, activated PARP1 has a vital role in apopto-
sis by translocation of the apoptosis inducing factor 
(AIF) from the mitochondria to the nucleus [60,61]. 
However, if there is a  high level of DNA damage, 
necrotic cell death is triggered by activating a large 
number of PARP1, consuming NAD+ and the ensuing 
ATP depletion [3]. The role of PARP1 activation cas-
cade has also been demonstrated in neuronal stem 
cell transplantation after brain injury in rats [27], as 
well as PARP1 is also activated in the ischemia-reper-
fusion injury [55], and the early activation of PARP1 
after cold lesion that is – at least in part – related 
to neuronal NO synthetase (nNOS) induction [16]. 
The role of PARP1 has been revealed in the regulation 
of glycogen synthase kinase-3 (GSK3) that is respon-
sible for the hyperphosphorylation of tau [54], and 
the amyloid peptide affected signal transduction to 
PARP1 in Alzheimer’s disease [2].
It has been demonstrated that PARP1 has a role 
in the BRCA1/BRCA2 mutated breast carcinomas 
because PARP1 inhibitors can trigger the effective-
ness of the chemotherapeutic agents by inhibiting 
the SSB-repair, when the double-stranded DNA repair 
is also diminished by the BRCA mutation [11]. The role 
of PARP1 has been described in other tumours such 
as breast [51], ovarian [6], pancreatic carcinomas [24], 
gastric carcinomas [62], prostate carcinomas [53], 
melanomas [13,40] and glioblastomas [12,21] but has 
not been investigated in meningiomas yet.
p53 is one of the most significant tumour sup-
pressor proteins, encoded by the TP53 gene on 
the short arm of chromosome 17 (17p13.1) [17,33]. 
The physiological functions of p53 are cell cycle regu-
lation and conservation of the stability of the genome 
by preventing mutations. The 393 amino acid long, 
43.7 kDa weight protein has 7 domains, such as two 
activation domains (AD1 and AD2), a  proline-rich 
domain, a DNA-binding core domain (DBD), a signal-
ling domain, a  homo-oligomerisation domain (OD) 
and a C-terminal downregulation domain. p53 can be 
activated by DNA damage, oxidative stress, osmotic 
shock, ribonucleotide depletion or oncogene expres-
sion. The activation is marked by an increase in the 
half-life of p53 and a change of its conformation [22]. 
Mdm2 is responsible for the low level of p53 in an 
unstressed cell, by binding to p53 and preventing its 
action, and it also transports p53 to the cytosol, and 
attaches ubiquitin to it covalently.
The anticancer activity of p53 works through sev-
eral mechanisms: it activates DNA repair proteins, 
induces growth arrest at the G1/S regulation point 
through p21 [10] or initiates apoptosis if the DNA 
damage is irreversible. Mutagens can damage TP53 
causing unregulated cell proliferation; more than 
50 percent of human tumours contain a deletion or 
mutation of the TP53 gene [15]. p53 was voted the 
molecule of the year in 1993 by the Science maga-
zine [25], due to its key roles.
The role of p53 has already been examined in the 
meningiomas: some of the examinations ended with 
negative or equivocal findings [43,48-50], but some 
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of them showed a  significant correlation between 
the p53 status and the grade or recurrence of the 
tumour [4,7,8,19,20,28,37,41,44,46,57]. It is also de- 
scribed that p53 immunopositive cells are more fre-
quent in the perinecrotic areas of post-embolised 
cases than in preserved parts of the tumour [39].
Several theses have been written about the inter-
action between the PARP1 and the p53. Wieler et al. 
showed that the inhibition of endogenous PARP1 
functions suppresses the transactivation function of 
p53 in response to ionizing radiation; hence PARP1 
is a key regulator of the p53 response to DNA dam-
age [58]. Malanga et al. showed that ADP-ribose 
polymers play a role in regulating the DNA binding 
properties of p53 by preventing and reversing p53 
binding to the palindromic p53 consensus sequence 
[36]. Lee et al. has recently discovered a novel role 
for PARylation of p53 in the gene-specific regulation 
of the transcriptional mode of p53 on the promoter 
of MTA1 [30]. Godoy et al. revealed overexpression 
of PARP1 and p53 in high-grade and advanced stage 
tumours in epithelial ovarian cancer, and it indicat-
ed that these 2 markers might serve as a  marker 
of aggressive disease behaviour [14]. Sabisz et al. 
showed the crucial part of PARP1 activity in the 
maintenance of the G2 arrest induced by DNA dam-
aging drugs; thus, inhibitors of PARP1 may be used 
as non-genotoxic agents to activate p53 in cancer 
cells with non-functional p53 pathways [52]. PARyla-
tion of transcription factors such as p53, NFkB, and 
Sp1 prevents their binding to DNA and formation of 
transcription complexes [42].
The aim of this study is to find any correlation 
between the PARP1 and p53 immunostaining and the 
WHO grade of the tumours, and between the PARP1 
and p53 immunopositivity. 
Material and methods
The histological slides of 31 meningioma patients 
have been studied. Patients have been divided into 
three groups according to the WHO Classification of 
Tumours of the Central Nervous System [34]. After 
the surgical removal, sections were created and 
stained for haematoxylin-eosin (H&E) from forma-
lin-fixed and paraffin-embedded (FFPE) blocks for 
a routine diagnostic procedure in the Institute of Pa-
thology. All of the cases have been revised by a con-
sultant neuropathologist (TH).
Immunohistochemistry (IHC) has been performed 
according to standardized methods as described in 
detail, in earlier publications [16,17]. In brief, 4 µm 
thick sections from FFPE blocks have been stained for 
PARP1 rabbit polyclonal antibody (ab6079) (Abcam 
Plc., Cambridge, England) and p53 DO-7 mouse mono-
clonal antibody (M7001) (DAKO, Denmark) according 
to the manufacturer’s protocol. Using a 1 : 500 and 
1 : 700 dilution for PARP1 and p53, respectively, with 
Novocastra Bond™ Polymer Refine Detection kit on 
Leica Bond Max™ fully automated IHC stainer, with 
negative controls (Fig. 1).
100 cells in 10 fields of vision on 40x magnifica-
tion have been examined; the staining intensity has 
been evaluated as none (0), weak (1+), moderate (2+) 
and strong (3+) from all of the slides for both PARP1 
and p53 (Fig. 2). We have created two parameters in 
all cases regarding to the staining intensity (Si) ratio 
of the 1+, 2+ and 3+ cells Si1-3, and ratio of the 2+ 
and 3+ cells Si2-3, similarly as HER2 immunohisto-
chemistry evaluation in breast carcinomas (Table I). 
The results have been analysed by SPSS 19.0 for 
Windows statistical software. After comparing with 
Kruskal-Wallis H test the Si1-3 and Si2-3, perform-
ing Mann-Whitney U  test on all of the grade pairs 
for both PARP1 and p53. Next, we have created two 
groups – low grade (WHO grade I) and high grade 
(WHO grade II and WHO grade III) [23] and have 
compared them by Mann-Whitney U  test. We also 
have performed Spearman’s rank order correlation 
analysis to determine whether there is any correla-
tion between the PARP1 and p53 immunopositivity.
Ethical approval has been sought from the Insti-
tutional Research Ethics Committee. 
Results
Both PARP1 and p53 have been expressed in all 
of the 41 cases. 
There was a  significant correlation between 
tu mour grade and presence of PARP1 expression 
(stain ing intensity (Si)1-3) (p = 0.001) and presence 
of explicit positivity (Si2-3) for p53 (p = 0.012), respec-
tively, with Kruskal-Wallis H test. In contrast, there 
was no statistically significant association between 
grade and Si2-3 for PARP1, Si1-3 for p53, p = 0.523 and 
p = 0.141, respectively.
As next, we have compared different grades and 
performed Mann-Whitney U test. The Si1-3 for PARP1 
between grade I and grade II, as well as grade II and 
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grade III (Fig. 3A); and the Si2-3 for p53 between 
grade I  and grade III (Fig. 3B) significantly correlat-
ed with the WHO grades (p = 0.001 and p = 0.005, 
p = 0.002, respectively). Grade II tumours showed the 
highest mean index of the PARP1 staining (Fig. 3A), 
while grade III tumours had the highest staining 
index for p53 (Fig. 3B).
The Mann-Whitney U test, performed on the low-
grade and high-grade groups, showed a significant 
correlation between Si1-3 for PARP1 (Fig. 3C) and 
Si2-3 for p53 (Fig. 3D), p = 0.028 and p = 0.018, res-
pectively.
Among grade I  tumours there were 11 menin-
gothelial, 8 transitional, 1 secretory, 1 fibrous and 
1 microcystic; among grade II tumours – 8 atypical 
and 3 clear cell; all the grade III tumours were ana-
plastic (i.e. not papillary and rhabdoid). There was no 
significant difference between the staining intensity 
of PARP and p53 between subtypes of any grades; 
however, the case numbers were rather low to make 
statistically valid comparisons.
There was no significant correlation between 
PARP1 and p53 with Spearman’s rank order correla-
tion analysis (Fig. 4). 
Discussion
Meningiomas are one of the most frequent intra-
cranial tumours with diverse morphological variants. 
The current WHO classification [34] distinguishes 
13 histological types. Nine of them belong to grade I; 
2 and 2 belong to grade II and grade III, respectively. 
There are morphological criteria that define atypi-
cal (WHO grade II) and anaplastic (WHO grade III) 
meningiomas; however, the distinction is often dif-
ficult. Until now there has been no highly trusted 
immunohistochemical marker that can separate the 
different WHO grades reliably.
PARP1 protein role has been demonstrated in the 
repair of the damaged DNA, however this protein 
also has an important role in the caspase indepen-
dent apoptotic pathway and in necrotic cell death. 
p53 is one of the most important tumour suppressor 
proteins, it has a  role in almost half of the human 
tumours. Several studies have been performed 
about the p53 marker, but those ended with equiv-
ocal results. PARP1 protein expression in meningio-
mas has not been examined yet.
In this study, all of the 41 cases showed immu-
nopositivity for both PARP1 and p53. The proportion 
Fi
g.
 2
. R
ep
re
se
nt
at
iv
e 
im
ag
es
 o
f 
th
e 
di
ff
er
en
t 
st
ai
ni
ng
 in
te
ns
it
ie
s.
 Im
m
un
os
ta
in
in
g 
is
 p
er
fo
rm
ed
 f
or
 p
53
 (
A
, B
, C
, D
) 
an
d 
PA
RP
1 
(E
, F
, G
, H
). 
Th
er
e 
ar
e 
ne
ga
ti
ve
 (A
, E
), 
w
ea
k 
– 
1+
 (B
, F
), 
m
od
er
at
e 
– 
2+
 (C
, G
) a
nd
 s
tr
on
g 
– 
3+
 (D
, H
) p
os
it
iv
e 
ce
lls
. (
PA
RP
1 
– 
po
ly
(A
D
P-
ri
bo
se
) p
ol
ym
er
as
e 
1)
 (s
ca
le
 b
ar
 1
0 
µm
). 
A E
B F
C G
D H
116 Folia Neuropathologica 2014; 52/2
Tamás Csonka, Balázs Murnyák, Rita Szepesi, Andrea Kurucz, Álmos Klekner, Tibor Hortobágyi
Patient 
No.
Slide 
No.
WHO 
Grade
Subtype
PARP1 p53
0 1+ 2+ 3+ Si1-3 Si2-3 0 1+ 2+ 3+ Si1-3 Si2-3
1 1 I Meningothelial 5 85 9 1 0.95 0.1 49 34 14 3 0.51 0.17
2 2 I Meningothelial 16 39 37 8 0.84 0.45 49 43 8 0 0.51 0.08
3 3 I Meningothelial 22 74 4 0 0.78 0.04 70 27 3 0 0.3 0.03
4 4 I Transitional 10 65 25 0 0.9 0.25 46 50 4 0 0.54 0.04
5 5 I Meningothelial 26 50 13 11 0.74 0.24 57 39 4 0 0.43 0.04
6 6 I Meningothelial 8 83 9 0 0.92 0.09 76 24 0 0 0.24 0
7 7 I Transitional 32 66 2 0 0.68 0.02 75 24 1 0 0.25 0.01
8 8 I Meningothelial 15 83 2 0 0.85 0.02 52 34 14 0 0.48 0.14
9 9 I Secretory 22 75 3 0 0.78 0.03 75 17 7 1 0.25 0.08
10 10 I Meningothelial 23 37 38 2 0.77 0.4 71 23 6 0 0.29 0.06
11 11 I Fibrous 21 30 24 25 0.79 0.49 47 50 3 0 0.53 0.03
12 12 I Transitional 15 66 19 0 0.85 0.19 53 38 9 0 0.47 0.09
13 13 I Meningothelial 7 93 0 0 0.93 0 86 12 2 0 0.14 0.02
14 14 I Meningothelial 11 68 20 1 0.89 0.21 76 23 1 0 0.24 0.01
15 15 I Microcystic 5 36 59 0 0.95 0.59 83 17 0 0 0.17 0
16 16 I Transitional 10 85 4 1 0.9 0.05 52 43 5 0 0.48 0.05
17 17 I Transitional 6 89 5 0 0.94 0.05 73 21 6 0 0.27 0.06
18 18 I Transitional 16 33 48 3 0.84 0.51 79 18 3 0 0.21 0.03
19 19 II Atypical 10 77 11 2 0.9 0.13 60 30 10 0 0.4 0.1
20 20 II Atypical 8 64 26 2 0.92 0.28 76 24 0 0 0.24 0
21 21 II Atypical 1 67 32 0 0.99 0.32 85 13 2 0 0.15 0.02
22 22 II Clear cell 2 80 18 0 0.98 0.18 68 29 3 0 0.32 0.03
23 23 II Atypical 14 71 10 5 0.86 0.15 78 18 4 0 0.22 0.04
23 24 I Transitional 9 72 16 3 0.91 0.19 69 31 0 0 0.31 0
24 25 II Atypical 6 71 21 2 0.94 0.23 80 18 2 0 0.2 0.02
25 26 II Atypical 1 84 15 0 0.99 0.15 72 23 5 0 0.28 0.05
25 27 II Clear cell 1 44 53 2 0.99 0.55 44 39 15 2 0.56 0.17
25 28 II Clear cell 0 27 49 24 1 0.73 38 32 27 3 0.62 0.3
25 29 I Meningothelial 10 81 9 0 0.9 0.09 67 29 4 0 0.33 0.04
25 30 I Meningothelial 4 77 16 3 0.96 0.19 71 21 6 2 0.29 0.08
25 31 I Transitional 9 82 9 0 0.91 0.09 67 27 6 0 0.33 0.06
26 32 II Atypical 0 33 63 4 1 0.67 35 39 26 0 0.65 0.26
27 35 III Anaplastic 10 81 9 0 0.9 0.09 59 29 10 2 0.41 0.12
27 34 III Anaplastic 8 42 40 10 0.92 0.5 30 47 22 1 0.7 0.23
27 33 II Atypical 4 83 10 3 0.96 0.13 71 21 7 1 0.29 0.08
28 36 III Anaplastic 10 74 15 1 0.9 0.16 42 28 17 13 0.58 0.3
28 37 III Anaplastic 20 66 14 0 0.8 0.14 49 20 17 14 0.51 0.31
28 38 III Anaplastic 4 47 48 1 0.96 0.49 79 19 2 0 0.21 0.02
29 39 III Anaplastic 14 71 14 1 0.86 0.15 68 22 7 3 0.32 0.1
30 40 III Anaplastic 25 73 2 0 0.75 0.02 54 26 13 7 0.46 0.2
31 41 III Anaplastic 28 62 10 0 0.72 0.1 76 15 9 0 0.24 0.09
Table I. Data sheet on cell counts showing staining intensities and their respective proportion to all counted cells.
Staining index (Si)1-3 is the ratio of the immunopositive (1+, 2+, 3+) cells; and the Si2-3 is the ratio of the 
intense positive (2+, 3+) cells. (PARP1 – poly(ADP-ribose) polymerase 1) 
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Fig. 3. p53 and PARP staining intensity varies according to the tumour grade. Mean values of the staining 
index (Si)1-3 for PARP1 (A, C) and Si2-3 for p53 (B, D) regarding to the WHO grades (A, B), and low grade – 
WHO grade I and high grade – WHO grade II and WHO grade III (C, D). Error bars ± standard error of mean 
(SEM). p values are calculated by Mann-Whitney U test. (PARP1 – poly(ADP-ribose) polymerase 1; staining 
index (Si)1-3 is the ratio of the immunopositive (1+, 2+, 3+) cells; and the Si2-3 is the ratio of the intense 
positive (2+, 3+) cells).
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of positive cells (Si1-3) was higher in grade II tumours 
for PARP1, as compared to grade I  and grade III 
meningiomas, respectively. Increased immunoposi-
tivity (Si2-3) was noted in grade III tumours for p53. 
Comparing the immunopositive cells in the low-
grade meningiomas (grade I) and in the high-grade 
meningiomas (grade II and grade III) we found more 
immunopositive cells (Si1-3) for PARP1 and a higher 
staining intensity (Si2-3) for p53 in the high-grade 
tumours.
Performing a  Spearman’s rank order correlation 
and linear regression, there was no statistical cor-
relation between either the presence of positivity or 
the intense immunoreactions for p53 and PARP1, 
thus the expression of these two proteins does 
not appear to be related to each other. We suggest 
that PARP1 activation increases in grade II tumours 
to cope with the DNA damage, whereas in grade 
III tumours PARP1 activity is decreased as a conse-
quence of apoptotic-necrotic cell death and preced-
ing overactivation and consecutive consumption of 
the protein and substrates.
Our data confirm that p53 protein plays a role in 
meningiomas, and indicate that the p53 activation 
might be a late event in the progression of meningo-
thelial neoplasms.
Although further studies are necessary to elu-
cidate the role of PARP1 and p53 in meningiomas, 
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our data indicate that PARP1 and p53 immunohis-
tochemistry represents useful and simple methods 
aiding the accurate diagnosis and grading of menin-
giomas.
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